NXL 004
Alternative Names: NeuroD1 gene therapy - NeuExcell Therapeutics; NXL-004Latest Information Update: 17 Jul 2024
At a glance
- Originator NeuExcell Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; NEUROD1 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Glioblastoma
Most Recent Events
- 31 May 2024 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 22 Mar 2024 Clinical trials in Glioblastoma in China (Parenteral)
- 19 Dec 2023 Preclinical trials in Glioblastoma in USA (Parenteral) prior to December 2023